Pedro Oyuela

1.6k total citations · 1 hit paper
16 papers, 1.2k citations indexed

About

Pedro Oyuela is a scholar working on Pathology and Forensic Medicine, Oncology and Rheumatology. According to data from OpenAlex, Pedro Oyuela has authored 16 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 5 papers in Oncology and 5 papers in Rheumatology. Recurrent topics in Pedro Oyuela's work include Multiple Sclerosis Research Studies (12 papers), Polyomavirus and related diseases (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Pedro Oyuela is often cited by papers focused on Multiple Sclerosis Research Studies (12 papers), Polyomavirus and related diseases (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Pedro Oyuela collaborates with scholars based in United States, United Kingdom and Czechia. Pedro Oyuela's co-authors include David Margolin, Alasdair Coles, Edward Fox, Cary Twyman, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Michael Panzara, Christian Confavreux and Jeffrey Cohen and has published in prestigious journals such as The Lancet, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Pedro Oyuela

15 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

2012 884 citations Alasdair Coles, Cary Twyman et al. The Lancet profile →

Peers

Countries citing papers authored by Pedro Oyuela

Since Specialization

Citations

This map shows the geographic impact of Pedro Oyuela's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Oyuela with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Oyuela more than expected).

Fields of papers citing papers by Pedro Oyuela

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro Oyuela. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Oyuela. The network helps show where Pedro Oyuela may publish in the future.

Co-authorship network of co-authors of Pedro Oyuela

This figure shows the co-authorship network connecting the top 25 collaborators of Pedro Oyuela. A scholar is included among the top collaborators of Pedro Oyuela based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro Oyuela. Pedro Oyuela is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Prevalence of Second Cancers in Patients with Polycythemia Vera (PV): A Retrospective Analysis of US Real-World Claims Data 2023 ·Blood ·Naveen Pemmaraju, Alina Markova, Lucia Masárová, Nancy L. Reaven, Susan E. Funk, Pedro Oyuela, Frank H. Valone, (unknown), (unknown), (unknown), Arturo Molina, Suneel Gupta	0
2	Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera 2023 ·Blood ·Andrew Kuykendall, Abdulraheem Yacoub, Nancy L. Reaven, Susan E. Funk, Pedro Oyuela, Frank H. Valone, (unknown), (unknown), (unknown), Arturo Molina, Suneel Gupta	1
3	Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) Program 2015 ·International Journal of MS Care ·Christina Caon, Marie Namey, (unknown), (unknown), Pedro Oyuela, David Margolin, Marco Rizzo	33
4	Successful Detection and Management of Immune Thrombocytopenia in Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple Sclerosis (P2.198) 2014 ·Neurology ·Adam Cuker, Roberto Stasi, Jeffrey Palmer, Pedro Oyuela, David Margolin, Ann Bass	3
5	Thyroid Autoimmune Adverse Events in Patients Treated with Alemtuzumab for Relapsing-remitting Multiple Sclerosis: Four-year Follow-up of the CARE-MS Studies (P2.199) 2014 ·Neurology ·Cary Twyman, Pedro Oyuela, Jeffrey Palmer, David Margolin, Colin Dayan	11
6	Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study 2014 ·Multiple Sclerosis and Related Disorders ·Xavier Montalbán, Jihad Inshasi, Alasdair Coles, HP Hartung, Eva Havrdová, Krzysztof Selmaj, David Margolin, (unknown), Pedro Oyuela	3
7	Safety of Using Disease-modifying Therapy Post-alemtuzumab Treatment in Patients With Relapsing-remitting Multiple Sclerosis in the Core and Extension Phases of CAMMS223, CARE-MS I, and CARE-MS II Studies (P2.201) 2014 ·Neurology ·Keith R. Edwards, Christopher LaGanke, Pedro Oyuela, Jeffrey Palmer, David Margolin	2
8	Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study 2014 ·Multiple Sclerosis and Related Disorders ·B. C. Kieseier, Mohammad Ali Sahraian, Alasdair Coles, HP Hartung, Eva Havrdová, Krzysztof Selmaj, David Margolin, (unknown), Pedro Oyuela	6
9	Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis 2013 ·The Journal of Clinical Endocrinology & Metabolism ·Gilbert H. Daniels, Anton Vladić, Vesna Brinar, (unknown), WILLIAM A. VALENTE, Pedro Oyuela, Jeffrey Palmer, David Margolin	111
10	Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001) 2013 ·Neurology ·Edward Fox, Douglas L. Arnold, Jeffrey Cohen, Alasdair Coles, Christian Confavreux, Hans Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Cary Twyman, Anton Vladić, David Margolin, Pedro Oyuela, Michael Panzara, Alastair Compston	11
11	Detection, Incidence, and Management of Thyroid Autoimmunity in Comparison of Alemtuzumab and Rebif® in Multiple Sclerosis (CARE-MS) I and II (P01.173) 2013 ·Neurology ·Tamara Miller, Douglas L. Arnold, Jeffrey Cohen, Alasdair Coles, Christian Confavreux, Edward Fox, Hans Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Stephen Lake, David Margolin, Pedro Oyuela, Michael Panzara, Alastair Compston	1
12	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial breakdown → 2012 ·The Lancet ·Alasdair Coles, Cary Twyman, Douglas L. Arnold, Jeffrey Cohen, Christian Confavreux, Edward Fox, Hans-Peter Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Tamara Miller, Elizabeth Fisher, Rupert Sandbrink, Stephen Lake, David Margolin, Pedro Oyuela, Michael Panzara, D. A. S. Compston	884
13	Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing–remitting multiple sclerosis 2012 ·Multiple Sclerosis and Related Disorders ·David Meyer, Alasdair Coles, Pedro Oyuela, Annie Purvis, David Margolin	29
14	Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis I (CARE-MS I) (S41.007) 2012 ·Neurology ·Eva Havrdová, Douglas L. Arnold, (unknown), Alasdair Coles, C Confavreux, Edward Fox, Hans‐Peter Hartung, Krzysztof Selmaj, H L Weiner, Vesna Brinar, Gavin Giovannoni, M. Stojanovic, Stephen Lake, David Margolin, Pedro Oyuela, (unknown), Alastair Compston	2
15	Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif(R) in Multiple Sclerosis I (CARE-MS I) (S41.006) 2012 ·Neurology ·Krzysztof Selmaj, Douglas L. Arnold, Vesna Brinar, J. A. Cohen, Alasdair Coles, C Confavreux, Edward Fox, Gavin Giovannoni, Hans‐Peter Hartung, Eva Havrdová, M. Stojanovic, H L Weiner, Stephen Lake, David Margolin, Pedro Oyuela, (unknown), A. Compston	3
16	A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis 2011 ·Blood ·Adam Cuker, Alasdair Coles, H. R. Sullivan, Edward Fox, Mark P. Goldberg, Pedro Oyuela, Annie Purvis, Diana S. Beardsley, David Margolin	79

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact